what should you eat when on tirzepatide Meal Plan Foods to Avoid on Tirzepatide:

For example, a 1000mAh battery with a 10C rating can release 10 amps steadily

Never recap needles by hand, as needle-stick injuries are a significant infection risk

To view or add a comment, sign in 876 followers

10.1007/s00701-010-0750-2 Acta Neurochir (Wien) 113 WangH.LinD.YuQ.LiZ.LenahanC.DongY.et al (2021)

Mechanism of Action Binds to insulin receptors (tyrosine kinase receptors) on target cells Promotes: Glucose uptake by muscle and adipose tissue Glycogen synthesis in liver and muscle Inhibition of gluconeogenesis and glycogenolysis Fat and protein metabolism regulation Net effect: blood glucose Pharmacokinetics Onset: 3060 minutes (subcutaneous) Peak: 24 hours Duration: 58 hours Route: Subcutaneous, IV, IM IV use: For rapid correction of hyperglycemia or diabetic ketoacidosis (DKA) Type 1 diabetes mellitus meal-time glucose control Type 2 diabetes mellitus when oral agents are insufficient Diabetic ketoacidosis (DKA) IV infusion Hyperosmolar hyperglycemic state (HHS) IV infusion Perioperative glucose control Adverse Effects Hypoglycemia: Most common sweating, tremor, dizziness, confusion Lipodystrophy: At injection site (rotate sites) Allergic reactions: Rare (rash, itching, anaphylaxis) Hypokalemia: Especially with high-dose IV insulin (shift of K into cells) Precautions Monitor blood glucose closely Adjust dose for meals, exercise, illness, or other medications Caution in renal/hepatic impairment Drug Interactions Sulfonylureas / meglitinides: risk of hypoglycemia Beta-blockers: Mask hypoglycemia symptoms Corticosteroids / thiazides: May blood glucose require higher insulin dose Class: Short-acting insulin Onset/Peak/Duration: 3060 min / 24 hr / 58 hr Uses: DKA, HHS, postprandial glucose control, Type 1 & 2 diabetes Major adverse effect: Hypoglycemia, lipodystrophy, hypokalemia Mnemonic for Insulin Action (GIG) G Glucose uptake I Inhibits gluconeogenesis G Glycogen synthesis To view or add a comment, sign in 2025 Perspective on Resistant Hypertension in CKD Part 2